BAYER LAUNCH OF CHEK-STIX OTC URINARY TRACT INFECTION TEST KIT EXPECTED BY EARLY 1997; KIT IS ONE OF TWO UTI TESTS TO GAIN 510(K) CLEARANCE FROM FDA IN JULY
This article was originally published in The Gray Sheet
Bayer plans to introduce its Chek-Stix UTI Self-Test over-the-counter test kit for urinary tract infections by early 1997, the company says. Launch of the kit, which received FDA 510(k) clearance on July 5, could make Bayer the first company with an over-the-counter UTI test on the U.S. market.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.